MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

Liu,Dongxiao; Sun,Qingmin; Liang,Song; Xu,Linlin; Luo,Xuan; Zhao,Xiaomei; Wang,Xuerong; Yang,Li

doi:10.3892/mmr.2012.1191

MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

Authors:
- Dongxiao Liu
- Qingmin Sun
- Song Liang
- Linlin Xu
- Xuan Luo
- Xiaomei Zhao
- Xuerong Wang
- Li Yang
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of South-east University, The Second Hospital of Nanjing, Nanjing 210003, P.R. China, Department of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, P.R. China, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China, Department of Pharmacology, Nanjing Medical University, Nanjing 210029, P.R. China
Published online on: November 21, 2012 https://doi.org/10.3892/mmr.2012.1191
Pages: 642-648

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA-27a (miR‑27a) is an oncogene that contributes to drug resistance in various types of cancer. However, the involvement of miR‑27a in gastric cancer has yet to be elucidated. Perifosine is an alkylphospholipid exhibiting antitumor activity as shown in both preclinical studies and clinical trials. The effects of perifosine on gastric cancer have yet to be determined. Therefore, this study was conducted to detect the role of miR‑27a and perifosine in human gastric cancer. miR‑27a was found to be expressed in human gastric cancer tissues and cell lines by quantitative reverse-transcription polymerase chain reaction (qRT‑PCR). The correlation between miR‑27a expression and clinicopathological characteristics of gastric cancer. We also explored the growth inhibitory effect of perifosine on human gastric cancer cells with or without co‑targeting miR‑27a by sulforhodamine B (SRB) assay. The results showed that miR‑27a expression was significantly upregulated in gastric cancer tissues, compared with their non‑tumor adjacent tissues. High expression levels of miR‑27a were associated with poor tumor histological grade (P=0.037). MiR‑27a inhibitors suppressed the growth of MGC‑803 cells. Assay results showed that perifosine exerted its activity selectively on the AGS cell line and the growth inhibitory effect of perifosine was enhanced significantly in combination with miR‑27a inhibitors in MGC‑803 cells. In conclusion, our results demonstrated that miR‑27a may be a therapeutic target and potential prognostic biological marker in gastric cancer. MiR‑27a inhibitors alone or in combination with perifosine may be a novel therapeutic approach against gastric cancer.

View Figures

View References

1	Pisani P, Parkin DM, Bray F and Ferlay J: Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 83:870–873. 1999. View Article : Google Scholar : PubMed/NCBI
2	Danaei G, Vander Hoorn S, Lopez AD, Murray CJ and Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 366:1784–1793. 2005. View Article : Google Scholar : PubMed/NCBI
3	Orditura M, De Vita F, Muto P, et al: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg. 145:233–238. 2010. View Article : Google Scholar : PubMed/NCBI
4	Milne AN, Carneiro F, O’Morain C and Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 126:615–628. 2009. View Article : Google Scholar : PubMed/NCBI
5	Dykxhoorn DM: MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 70:6401–6406. 2010. View Article : Google Scholar : PubMed/NCBI
6	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yang H, Kong W, He L, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhu H, Wu H, Liu X, et al: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
10	Mertens-Talcott SU, Chintharlapalli S, Li X and Safe S: The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67:11001–11011. 2007. View Article : Google Scholar
11	Pathi SS, Jutooru I, Chadalapaka G, et al: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res. 9:195–202. 2011. View Article : Google Scholar : PubMed/NCBI
12	Liu T, Tang H, Lang Y, Liu M and Li X: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 273:233–242. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sun Q, Cong R, Yan H, et al: Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep. 22:563–567. 2009.PubMed/NCBI
14	Zhao X, Yang L and Hu J: Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res. 30:552011. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Li M, Han Y, et al: Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 55:2545–2551. 2010. View Article : Google Scholar : PubMed/NCBI
16	Li Z, Hu S, Wang J, et al: MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 119:125–130. 2010. View Article : Google Scholar : PubMed/NCBI
17	Feng DD, Zhang H, Zhang P, et al: Down-regulated miR-331–5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med. 15:2164–2175. 2011.
18	Vink SR, Schellens JH, van Blitterswijk WJ and Verheij M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs. 23:279–286. 2005. View Article : Google Scholar : PubMed/NCBI
19	Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B and Engel J: D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer. 33:442–446. 1997. View Article : Google Scholar : PubMed/NCBI
20	Nyakern M, Cappellini A, Mantovani I and Martelli AM: Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther. 5:1559–1570. 2006. View Article : Google Scholar
21	Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA and Roy KK: In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res. 10:5242–5252. 2004. View Article : Google Scholar
22	Van Ummersen L, Binger K, Volkman J, et al: A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 10:7450–7456. 2004.PubMed/NCBI
23	Richardson PG, Wolf J, Jakubowiak A, et al: Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 29:4243–4249. 2011. View Article : Google Scholar
24	Papazisis KT, Geromichalos GD, Dimitriadis KA and Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods. 208:151–158. 1997. View Article : Google Scholar : PubMed/NCBI
25	Ueda T, Volinia S, Okumura H, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
26	De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F and Orditura M: Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 36(Suppl 3): S11–S15. 2010.
27	Ruan K, Fang X and Ouyang G: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
28	Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol. 35:339–347. 2009. View Article : Google Scholar : PubMed/NCBI
29	Vink SR, Lagerwerf S, Mesman E, et al: Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res. 12:1615–1622. 2006. View Article : Google Scholar : PubMed/NCBI
30	Momota H, Nerio E and Holland EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 65:7429–7435. 2005. View Article : Google Scholar : PubMed/NCBI
31	Gills JJ and Dennis PA: Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep. 11:102–110. 2009. View Article : Google Scholar : PubMed/NCBI